Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06682169 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 42 to 41 · Start date changed from estimate of Nov 2024 to Nov 20, 2024v3 Show 2 more changesShow less
    • Study sites: 42 to 41
    • Start date changed from estimate of Nov 2024 to Nov 20, 2024
  3. Interventions: Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab (Drug), Rovadicitinib (Drug) to Imatinib (Drug), Methotrexate (Drug), Mycophenolate mofetil (Drug), Rituximab (Drug), Rovadicitinib (Drug) Secondary endpoints: details revised at 1 of 13 entriesv2 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 13 entries
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can significantly improve the objective response rate of subjects at week 24.
Trial Details
NCT Number NCT06682169
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Graft-versus-host Disease
Enrollment 182 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov